NASDAQ:SCNI - Nasdaq - US09073Q3039 - ADR - Currency: USD
2.214
-0.05 (-2.04%)
The current stock price of SCNI is 2.214 USD. In the past month the price decreased by -22.6%. In the past year, price decreased by -38.5%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 18.04 | 327.31B | ||
AMGN | AMGEN INC | 13.94 | 155.58B | ||
GILD | GILEAD SCIENCES INC | 14.02 | 134.97B | ||
VRTX | VERTEX PHARMACEUTICALS INC | N/A | 113.22B | ||
REGN | REGENERON PHARMACEUTICALS | 11.5 | 55.03B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 40.38B | ||
ARGX | ARGENX SE - ADR | 94.29 | 33.10B | ||
ONC | BEONE MEDICINES LTD-ADR | 6.32 | 26.73B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.61B | ||
NTRA | NATERA INC | N/A | 23.47B | ||
INSM | INSMED INC | N/A | 18.70B | ||
BIIB | BIOGEN INC | 8.03 | 18.62B |
Scinai Immunotherapeutics Ltd. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunomodulation therapies for infectious diseases. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The firm's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
SCINAI IMMUNOTHERAPEUTICS LT
Jerusalem Biopark, 2Nd Floor, Hadassah Ein Kerem Campus
JERUSALEM IL
Employees: 31
Phone: 97289302529
The current stock price of SCNI is 2.214 USD. The price decreased by -2.04% in the last trading session.
The exchange symbol of SCINAI IMMUNOTHERAPEUTICS LT is SCNI and it is listed on the Nasdaq exchange.
SCNI stock is listed on the Nasdaq exchange.
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a market capitalization of 2.07M USD. This makes SCNI a Nano Cap stock.
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) currently has 31 employees.
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) has a resistance level at 2.22. Check the full technical report for a detailed analysis of SCNI support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SCNI does not pay a dividend.
The PE ratio for SCINAI IMMUNOTHERAPEUTICS LT (SCNI) is 1.04. This is based on the reported non-GAAP earnings per share of 2.12 and the current share price of 2.214 USD. Check the full fundamental report for a full analysis of the valuation metrics for SCNI.
The outstanding short interest for SCINAI IMMUNOTHERAPEUTICS LT (SCNI) is 0.06% of its float. Check the ownership tab for more information on the SCNI short interest.
ChartMill assigns a fundamental rating of 2 / 10 to SCNI. SCNI has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months SCNI reported a non-GAAP Earnings per Share(EPS) of 2.12.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 400.76% | ||
ROA | 19.61% | ||
ROE | 26.43% | ||
Debt/Equity | 0.03 |
ChartMill assigns a Buy % Consensus number of 83% to SCNI. The Buy consensus is the average rating of analysts ratings from 7 analysts.